Literature DB >> 24835642

Beyond the Brain: The Role of Brain-Derived Neurotrophic Factor in Viroimmune Responses to Antiretroviral Therapy among People Living with HIV with and without Alcohol Use.

María José Míguez-Burbano1, Luis Espinoza2, Diego Bueno3, Mayra Vargas3, Allison B Trainor4, Clery Quiros3, John E Lewis5, Deshratn Asthana5.   

Abstract

OBJECTIVE: Given the emerging data suggesting the key role of brain-derived neurotrophic factor (BDNF) in the immune system, we assessed longitudinally whether BDNF depletions induced by hazardous alcohol use (HAU) would impact a response to antiretroviral therapy (ART).
METHODS: In a prospective single-site cohort, virological and immunological responses to ART in 200 hazardous and 200 nonhazardous users were obtained, along with plasma BDNF levels.
RESULTS: Hazardous drinkers were more likely to have BDNF levels <4000 pg/mL (odds ratio [OR] = 1.6, P = .01). Participants with BDNF <4000 pg/mL were less likely to have CD4 counts of more than 500 cells/mm(3) (P = .02) and to achieve viral suppression over the follow-up period (OR = 1.5, P = .03). Multivariate analysis confirmed the significant role of HAU and low BDNF in predicting viroimmune responses.
CONCLUSION: Hazardous alcohol use was associated with BDNF alterations, which in turn were linked to a limited response to ART in terms of viral suppression and CD4 count improvements.
© The Author(s) 2014.

Entities:  

Keywords:  BDNF; CD4; HIV/AIDS; alcohol; viral load

Mesh:

Substances:

Year:  2014        PMID: 24835642      PMCID: PMC4508011          DOI: 10.1177/2325957414535253

Source DB:  PubMed          Journal:  J Int Assoc Provid AIDS Care        ISSN: 2325-9574


  22 in total

Review 1.  The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options.

Authors:  Lidia Gazzola; Camilla Tincati; Giusi Maria Bellistrì; Antonella d'Arminio Monforte; Giulia Marchetti
Journal:  Clin Infect Dis       Date:  2009-02-01       Impact factor: 9.079

2.  Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.

Authors:  Gilbert R Kaufmann; Hansjakob Furrer; Bruno Ledergerber; Luc Perrin; Milos Opravil; Pietro Vernazza; Matthias Cavassini; Enos Bernasconi; Martin Rickenbach; Bernard Hirschel; Manuel Battegay
Journal:  Clin Infect Dis       Date:  2005-06-24       Impact factor: 9.079

3.  Neurotrophins modulate the expression of chemokine receptors in the brain.

Authors:  Valeriya Avdoshina; Jody Becker; Lee A Campbell; Maia Parsadanian; Timothy Mhyre; Lino Tessarollo; Italo Mocchetti
Journal:  J Neurovirol       Date:  2010-11-30       Impact factor: 2.643

4.  Blood BDNF concentrations reflect brain-tissue BDNF levels across species.

Authors:  Anders B Klein; Rebecca Williamson; Martin A Santini; Christoffer Clemmensen; Anders Ettrup; Maribel Rios; Gitte M Knudsen; Susana Aznar
Journal:  Int J Neuropsychopharmacol       Date:  2010-07-07       Impact factor: 5.176

Review 5.  Sex issues in HIV-1-infected persons during highly active antiretroviral therapy: a systematic review.

Authors:  Emanuele Nicastri; Sebastiano Leone; Claudio Angeletti; Lucia Palmisano; Loredana Sarmati; Antonio Chiesi; Andrea Geraci; Stefano Vella; Pasquale Narciso; Angela Corpolongo; Massimo Andreoni
Journal:  J Antimicrob Chemother       Date:  2007-08-21       Impact factor: 5.790

6.  Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.

Authors:  Matthias Egger; Margaret May; Geneviève Chêne; Andrew N Phillips; Bruno Ledergerber; François Dabis; Dominique Costagliola; Antonella D'Arminio Monforte; Frank de Wolf; Peter Reiss; Jens D Lundgren; Amy C Justice; Schlomo Staszewski; Catherine Leport; Robert S Hogg; Caroline A Sabin; M John Gill; Bernd Salzberger; Jonathan A C Sterne
Journal:  Lancet       Date:  2002-07-13       Impact factor: 79.321

7.  Brain-derived neurotrophic factor inhibits human immunodeficiency virus-1/gp120-mediated cerebellar granule cell death by preventing gp120 internalization.

Authors:  Alessia Bachis; Eugene O Major; Italo Mocchetti
Journal:  J Neurosci       Date:  2003-07-02       Impact factor: 6.167

8.  Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy.

Authors:  Peter W Hunt; Steven G Deeks; Benigno Rodriguez; Hernan Valdez; Starley B Shade; Donald I Abrams; Mari M Kitahata; Melissa Krone; Torsten B Neilands; Richard J Brand; Michael M Lederman; Jeffrey N Martin
Journal:  AIDS       Date:  2003-09-05       Impact factor: 4.177

9.  Gender differences in immune reconstitution: a multicentric cohort analysis in sub-Saharan Africa.

Authors:  David Maman; Mar Pujades-Rodriguez; Fabien Subtil; Loretxu Pinoges; Megan McGuire; Rene Ecochard; Jean-François Etard
Journal:  PLoS One       Date:  2012-02-17       Impact factor: 3.240

10.  Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries.

Authors:  Paula Braitstein; Martin W G Brinkhof; François Dabis; Mauro Schechter; Andrew Boulle; Paolo Miotti; Robin Wood; Christian Laurent; Eduardo Sprinz; Catherine Seyler; David R Bangsberg; Eric Balestre; Jonathan A C Sterne; Margaret May; Matthias Egger
Journal:  Lancet       Date:  2006-03-11       Impact factor: 79.321

View more
  3 in total

1.  A central role for glial CCR5 in directing the neuropathological interactions of HIV-1 Tat and opiates.

Authors:  Sarah Kim; Yun Kyung Hahn; Elizabeth M Podhaizer; Virginia D McLane; Shiping Zou; Kurt F Hauser; Pamela E Knapp
Journal:  J Neuroinflammation       Date:  2018-10-10       Impact factor: 8.322

2.  Morphine exposure exacerbates HIV-1 Tat driven changes to neuroinflammatory factors in cultured astrocytes.

Authors:  Kenneth Chen; Thienlong Phan; Angel Lin; Luca Sardo; Anthony R Mele; Michael R Nonnemacher; Zachary Klase
Journal:  PLoS One       Date:  2020-03-25       Impact factor: 3.240

Review 3.  The Role of Brain Derived Neurotrophic Factor in HIV-Associated Neurocognitive Disorder: From the Bench-Top to the Bedside.

Authors:  Henry Michael; Thabisile Mpofana; Suvira Ramlall; Frasia Oosthuizen
Journal:  Neuropsychiatr Dis Treat       Date:  2020-01-31       Impact factor: 2.570

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.